Investing.com - LAVA Therapeutics NV (NASDAQ: LVTX) reported third quarter EPS of $-0.34, $0.15 better than the analyst estimate of $-0.49. Revenue for the quarter came in at $53K versus the consensus estimate of $0.
LAVA Therapeutics NV's stock price closed at $1.49. It is down -14.37% in the last 3 months and down -70.97% in the last 12 months.
LAVA Therapeutics NV saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See LAVA Therapeutics NV's stock price’s past reactions to earnings here.
According to InvestingPro, LAVA Therapeutics NV's Financial Health score is "good performance".
Check out LAVA Therapeutics NV's recent earnings performance, and LAVA Therapeutics NV's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar